TheEdgeResearch
Home / Stocks / VPTDF

VentriPoint Diagnostics Ltd. (VPTDF)

OTC Healthcare Medical - Devices
$0.05 ▲ +4.68%
Market Cap
$9.5M
Sector
Healthcare
Industry
Medical - Devices
Beta
0.04
52-Wk Range
0.04491-0.1367
CEO
Hugh MacNaught
Country
CA
Currency
USD

VentriPoint Diagnostics Ltd. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $0.05, up 4.68% on the session, giving a market capitalisation of $9.5M. On trailing twelve-month figures it carries a trailing P/E of -4.98, a net margin of -1568.5%. Its beta of 0.04 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-4.98
Price / Sales
84.84
Price / Book
-3.17
EV / EBITDA
-8.90
Gross margin
89.6%
Operating margin
-1624.5%
Net margin
-1568.5%
Return on equity
—
Debt / equity
-0.68
Current ratio
0.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
3
IPO date
2010-09-22
Headquarters
Toronto, ON, CA
About VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.

Comparable companies

VentriPoint Diagnostics Ltd. is most often compared with the following Healthcare names:

ALRTFANPCYASAPFBTCYCHHELUFFFNUMIFOASMYSRBCFZMSPF
More research on VPTDF
VPTDF technical analysis VPTDF TheEdge Score Compare against peers
Open full interactive analysis & DCF →